Strategic Wealth Advisors Group LLC purchased a new position in shares of Cerus Co. (NASDAQ:CERS) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 50,800 shares of the biotechnology company’s stock, valued at approximately $247,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Aperio Group LLC bought a new position in Cerus during the 2nd quarter worth approximately $27,000. Meristem Family Wealth LLC bought a new position in Cerus during the 2nd quarter worth approximately $56,000. Jefferies Group LLC bought a new position in Cerus during the 2nd quarter worth approximately $75,000. Jane Street Group LLC bought a new position in Cerus during the 2nd quarter worth approximately $93,000. Finally, Cubist Systematic Strategies LLC raised its holdings in Cerus by 1,108.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 20,551 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 18,851 shares during the last quarter. Hedge funds and other institutional investors own 74.26% of the company’s stock.
Several research firms have issued reports on CERS. Zacks Investment Research upgraded shares of Cerus from a “sell” rating to a “hold” rating in a report on Monday, October 7th. ValuEngine lowered shares of Cerus from a “buy” rating to a “hold” rating in a report on Monday, November 4th. BidaskClub lowered shares of Cerus from a “sell” rating to a “strong sell” rating in a report on Friday, October 25th. Stephens began coverage on shares of Cerus in a report on Thursday, August 22nd. They set an “overweight” rating and a $8.00 price target for the company. Finally, Stifel Nicolaus began coverage on shares of Cerus in a report on Tuesday, August 27th. They set a “buy” rating and a $7.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. Cerus has an average rating of “Hold” and a consensus price target of $7.63.
In other news, SVP Carol Moore sold 30,000 shares of Cerus stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $5.33, for a total value of $159,900.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Timothy B. Anderson sold 9,664 shares of Cerus stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $5.25, for a total value of $50,736.00. Following the completion of the transaction, the director now directly owns 177,649 shares in the company, valued at $932,657.25. The disclosure for this sale can be found here. Insiders have sold 58,459 shares of company stock valued at $312,129 in the last quarter. 7.26% of the stock is owned by company insiders.
Shares of NASDAQ:CERS traded down $0.13 during mid-day trading on Friday, hitting $4.11. The company had a trading volume of 612,600 shares, compared to its average volume of 864,339. Cerus Co. has a one year low of $3.95 and a one year high of $6.88. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.77 and a quick ratio of 2.31. The firm has a fifty day moving average price of $4.61 and a 200 day moving average price of $5.16. The company has a market capitalization of $607.59 million, a PE ratio of -9.34 and a beta of 1.60.
Cerus (NASDAQ:CERS) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.13) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.01). Cerus had a negative net margin of 100.38% and a negative return on equity of 100.59%. The business had revenue of $18.00 million for the quarter, compared to the consensus estimate of $17.69 million. During the same quarter last year, the business earned ($0.11) EPS. Cerus’s revenue for the quarter was up 16.9% compared to the same quarter last year. Research analysts expect that Cerus Co. will post -0.5 earnings per share for the current fiscal year.
Cerus Company Profile
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Featured Story: Understanding Market Liquidity
Want to see what other hedge funds are holding CERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerus Co. (NASDAQ:CERS).